"PUF_CASE_ID","PUF_FACILITY_ID","FACILITY_TYPE_CD","FACILITY_LOCATION_CD","AGE","SEX","RACE","SPANISH_HISPANIC_ORIGIN","INSURANCE_STATUS","MED_INC_QUAR_00","NO_HSD_QUAR_00","UR_CD_03","MED_INC_QUAR_12","NO_HSD_QUAR_12","UR_CD_13","CROWFLY","CDCC_TOTAL_BEST","SEQUENCE_NUMBER","CLASS_OF_CASE","YEAR_OF_DIAGNOSIS","PRIMARY_SITE","LATERALITY","HISTOLOGY","BEHAVIOR","GRADE","DIAGNOSTIC_CONFIRMATION","TUMOR_SIZE","REGIONAL_NODES_POSITIVE","REGIONAL_NODES_EXAMINED","DX_STAGING_PROC_DAYS","RX_SUMM_DXSTG_PROC","TNM_CLIN_T","TNM_CLIN_N","TNM_CLIN_M","TNM_CLIN_STAGE_GROUP","TNM_PATH_T","TNM_PATH_N","TNM_PATH_M","TNM_PATH_STAGE_GROUP","TNM_EDITION_NUMBER","ANALYTIC_STAGE_GROUP","CS_METS_AT_DX","CS_METS_EVAL","CS_EXTENSION","CS_TUMOR_SIZEEXT_EVAL","CS_METS_DX_BONE","CS_METS_DX_BRAIN","CS_METS_DX_LIVER","CS_METS_DX_LUNG","LYMPH_VASCULAR_INVASION","CS_SITESPECIFIC_FACTOR_1","CS_SITESPECIFIC_FACTOR_2","CS_SITESPECIFIC_FACTOR_3","CS_SITESPECIFIC_FACTOR_4","CS_SITESPECIFIC_FACTOR_5","CS_SITESPECIFIC_FACTOR_6","CS_SITESPECIFIC_FACTOR_7","CS_SITESPECIFIC_FACTOR_8","CS_SITESPECIFIC_FACTOR_9","CS_SITESPECIFIC_FACTOR_10","CS_SITESPECIFIC_FACTOR_11","CS_SITESPECIFIC_FACTOR_12","CS_SITESPECIFIC_FACTOR_13","CS_SITESPECIFIC_FACTOR_14","CS_SITESPECIFIC_FACTOR_15","CS_SITESPECIFIC_FACTOR_16","CS_SITESPECIFIC_FACTOR_17","CS_SITESPECIFIC_FACTOR_18","CS_SITESPECIFIC_FACTOR_19","CS_SITESPECIFIC_FACTOR_20","CS_SITESPECIFIC_FACTOR_21","CS_SITESPECIFIC_FACTOR_22","CS_SITESPECIFIC_FACTOR_23","CS_SITESPECIFIC_FACTOR_24","CS_SITESPECIFIC_FACTOR_25","CS_VERSION_LATEST","DX_RX_STARTED_DAYS","DX_SURG_STARTED_DAYS","DX_DEFSURG_STARTED_DAYS","RX_SUMM_SURG_PRIM_SITE","RX_HOSP_SURG_APPR_2010","RX_SUMM_SURGICAL_MARGINS","RX_SUMM_SCOPE_REG_LN_SUR","RX_SUMM_SURG_OTH_REGDIS","SURG_DISCHARGE_DAYS","READM_HOSP_30_DAYS","REASON_FOR_NO_SURGERY","DX_RAD_STARTED_DAYS","RAD_LOCATION_OF_RX","RX_SUMM_SURGRAD_SEQ","RAD_ELAPSED_RX_DAYS","REASON_FOR_NO_RADIATION","DX_SYSTEMIC_STARTED_DAYS","DX_CHEMO_STARTED_DAYS","RX_SUMM_CHEMO","DX_HORMONE_STARTED_DAYS","RX_SUMM_HORMONE","DX_IMMUNO_STARTED_DAYS","RX_SUMM_IMMUNOTHERAPY","RX_SUMM_TRNSPLNT_ENDO","RX_SUMM_SYSTEMIC_SUR_SEQ","DX_OTHER_STARTED_DAYS","RX_SUMM_OTHER","PALLIATIVE_CARE","RX_SUMM_TREATMENT_STATUS","PUF_30_DAY_MORT_CD","PUF_90_DAY_MORT_CD","DX_LASTCONTACT_DEATH_MONTHS","PUF_VITAL_STATUS","RX_HOSP_SURG_PRIM_SITE","RX_HOSP_CHEMO","RX_HOSP_IMMUNOTHERAPY","RX_HOSP_HORMONE","RX_HOSP_OTHER","PUF_MULT_SOURCE","PUF_REFERENCE_DATE_FLAG","RX_SUMM_SCOPE_REG_LN_2012","RX_HOSP_DXSTG_PROC","PALLIATIVE_CARE_HOSP","TUMOR_SIZE_SUMMARY_2016","METS_AT_DX_OTHER","METS_AT_DX_DISTANT_LN","METS_AT_DX_BONE","METS_AT_DX_BRAIN","METS_AT_DX_LIVER","METS_AT_DX_LUNG","NO_HSD_QUAR_2016","MED_INC_QUAR_2016","PUF_MEDICAID_EXPN_CODE","PHASE_I_RT_VOLUME","PHASE_I_RT_TO_LN","PHASE_I_DOSE_FRACT","PHASE_I_NUM_FRACT","PHASE_I_BEAM_TECH","PHASE_I_TOTAL_DOSE","PHASE_I_RT_MODALITY","PHASE_II_RT_VOLUME","PHASE_II_RT_TO_LN","PHASE_II_DOSE_FRACT","PHASE_II_NUM_FRACT","PHASE_II_BEAM_TECH","PHASE_II_TOTAL_DOSE","PHASE_II_RT_MODALITY","PHASE_III_RT_VOLUME","PHASE_III_RT_TO_LN","PHASE_III_DOSE_FRACT","PHASE_III_NUM_FRACT","PHASE_III_BEAM_TECH","PHASE_III_TOTAL_DOSE","PHASE_III_RT_MODALITY","NUMBER_PHASES_RAD_RX","RAD_RX_DISC_EARLY","TOTAL_DOSE","ADENOID_CYSTIC_BSLD","ADENOPATHY","AFP_POST_ORCH_RANGE","AFP_POST_ORCH_VALUE","AFP_PRE_INTERP","AFP_PRE_ORCH_RANGE","AFP_PRE_ORCH_VALUE","AFP_PRE_VALUE","AJCC_ID","AJCC_TNM_CLIN_M","AJCC_TNM_CLIN_N","AJCC_TNM_CLIN_N_SFX","AJCC_TNM_CLIN_STG_GRP","AJCC_TNM_CLIN_T","AJCC_TNM_CLIN_T_SFX","AJCC_TNM_PATH_M","AJCC_TNM_PATH_N","AJCC_TNM_PATH_N_SFX","AJCC_TNM_PATH_STG_GRP","AJCC_TNM_PATH_T","AJCC_TNM_PATH_T_SFX","AJCC_TNM_POST_PATH_M","AJCC_TNM_POST_PATH_N","AJCC_TNM_POST_PATH_N_SFX","AJCC_TNM_POST_PATH_STG_GRP","AJCC_TNM_POST_PATH_T","AJCC_TNM_POST_PATH_T_SFX","ALBUMIN_PRE_TX_LEVL","ANEMIA","B_SYMPTOMS","BASAL_DIAMETER","BETA2MG_PRE_TX_LVL","BEYOND_CAPSULE","BILIRUBIN_PRE_UNIT","BILIRUBIN_PRE_VALUE","BONE_INVASION","BRAIN_MOL_MARKERS","BRESLOW_THICKNESS","CA125_PRE_INTERP","CEA_PRE_INTERP","CEA_PRE_VALUE","CHROMOSOME_19QLOH","CHROMOSOME_1PLOH","CHROMOSOME_3_STATUS","CHROMOSOME_8Q_STAT","CREATININE_PRE_UNIT","CREATININE_PRE_VALU","CRM","ENE_CLIN_HN","ENE_CLIN_NOT_HN","ENE_PATH_HN","ENE_PATH_NOT_HN","ER_PERCENT_POS_OR_RNG","ER_SUMMARY","ER_TOTAL_ALLRED","ESOPH_EPICENTER","EXTRAVASC_MATRIX","FIBROSIS_SCORE","FIGO_STAGE","GEST_PROGNOST_INDEX","GLEASON_PAT_CLIN","GLEASON_PAT_PATH","GLEASON_SCORE_CLIN","GLEASON_SCORE_PATH","GLEASON_SCORE_TERTIARY_PT","GRADE_CLIN","GRADE_PATH","GRADE_PATH_POST","HCG_POST_ORCH_RANGE","HCG_POST_ORCH_VALUE","HCG_PRE_ORCH_RANGE","HCG_PRE_ORCH_VALUE","HER2_IHC_SUMMARY","HER2_ISH_DUAL_NUM","HER2_ISH_DUAL_RATIO","HER2_ISH_SINGLE_NUM","HER2_ISH_SUMMARY","HER2_OVERALL_SUMM","HERITABLE_TRAIT","HIGH_RISK_CYTOGENET","HIGH_RISK_HIST_FEAT","HIV_STATUS","IMMUNE_SUPP","INR_PRO_TIME","IPSI_ADRENAL_INVOL","JAK2","KI67","KIT_GENE_IHC","KRAS","LDH_POST_ORCH_RANGE","LDH_PRE_ORCH_RANGE","LDH_PRE_TX_LEVEL","LDH_PRE_TX_VALUE","LDH_UPPER_NORMAL","LN_DIST_MEDIAS_SCALN","LN_DISTANT_METHOD","LN_FEM_ING_PARA_APELV","LN_ITC","LN_LATERALITY","LN_METHOD_FEMING","LN_METHOD_PARA_AORT","LN_METHOD_PELVIC","LN_POS_AX_LEVELS_I_II","LN_SIZE","LNHN_LEVELS_I_III","LNHN_LEVELS_IV_V","LNHN_LEVELS_OTHER","LNHN_LEVELS_VI_VII","LYMPHOCYTOSIS","MAJOR_VEIN_INVOLV","METHYLATION_O6MGMT","MICROVASC_DENSITY","MITOTIC_COUNT_UVEA","MITOTIC_RATE_MELANO","MSI","MULTIGENE_METHOD","MULTIGENE_RESULTS","NCCN_IPI","NUM_CORES_EXAM","NUM_CORES_POS","NUM_NODES_EXAM_PARA_A","NUM_NODES_POS_PARA_A","NUM_PELV_NODES_EXAM","NUM_PELV_NODES_POS","ONCOTYPE_RISK_DCIS","ONCOTYPE_RISK_INVAS","ONCOTYPE_SCORE_DCIS","ONCOTYPE_SCORE_INV","ORGANOMEGALY","P_SCLER_CHOLANGITIS","PERCNT_NECROS_POST","PERINEURAL_INV","PERIPH_BLOOD_INV","PERITONEAL_CYTOL","PLEURAL_EFFUSION","PLEURAL_INV","PR_PERCENT_POS_OR_RNG","PR_SUMMARY","PR_TOTAL_ALLRED","PROSTATE_PATH_EXT","PSA","RSPNS_TO_NEOADJUVT","S_CAT_CLIN","S_CAT_PATH","SARCOMATOID","SCHEMA_DISC_1","SCHEMA_DISC_2","SCHEMA_DISC_3","SCHEMA_ID","SEP_NODULES","SLN_EXAM","SLN_POS","THICKNESS","THROMBOCYTOPENIA","TUMOR_DEPOSITS","TUMOR_GROWTH_PAT","ULCERATION","SENTINEL_LNBX_STARTED_DAY","REG_LN_DISS_STARTED_DAY","RESID_POST_CYTOREDU","NO_HSD_QUAR_2020","MED_INC_QUAR_2020","SARSCOV2_POS","SARSCOV2_POS_DAYS","SARSCOV2_TEST","Facility","URBAN_RURAL","GRADE_RECODE","REGIONAL_NODES_EXAMINED_notes","REGIONAL_NODES_POSITIVE_notes","SLN_EXAM_notes","SLN_POS_notes","cT_RECODE","cN_RECODE","cM_RECODE","cSTAGE_RECODE","pT_RECODE","pN_RECODE","pM_RECODE","pSTAGE_RECODE","MARGINS_RECODE","ANY_SURGERY","JOINT_SURG_MARGINS","SURGERY_MARGINS"
"Dbd2f9c45-3f8b-4a3a-8e9b-17349689b845","IKGDERPAKH","Academic/Research Program (includes NCI-designated comprehensive cancer centers)","Mountain",66,"Female","White","Non-Spanish; non-Hispanic","Medicare",NA,NA,NA,NA,NA,NA,NA,"Total Charlson Score of 0",0,"Initial diagnosis elsewhere and all or part of first course treatment or a decision not to treat was done at the reporting facility, NOS.",2009,"C445","Paired site, but lateral origin unknown; midline tumor.",8745,"Invasive or microinvasive","Cell type not determined, not stated or not applicable;unknown primaries; high grade dysplasia (adenocarcinoma in situ)","Positive histology",NA,NA,0,NA,"No surgical diagnosis or staging performed","cT1a","cN0","cM0","cStage I","pT1a","pN0",NA,"pStage I","6th Edition","Stage I",0,0,300,3,NA,NA,NA,NA,NA,55,0,5,999,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,20550,0,0,39,45,NA,"No residual tumor","No regional lymph node surgery","None",0,"None","Surgery performed",NA,"No radiation treatment",0,0,"Radiation therapy was not administered because it was not part of the planned first course treatment",NA,NA,"None, chemotherapy was not part of the planned first course of therapy",NA,"None, hormone therapy was not part of the planned first course of therapy",NA,"None, immunotherapy was not part of the planned first course of therapy","No transplant procedure or endocrine therapy was administered as part of first course therapy","No systemic therapy and/or surgical procedures",NA,"None","None",NA,"Alive","Alive",86.37,"Dead",45,"None, chemotherapy was not part of the planned first course of therapy","None, immunotherapy was not part of the planned first course of therapy","None, hormone therapy was not part of the planned first course of therapy","None","Only one CoC facility reported this case to NCDB",1,NA,"No surgical diagnostic or staging procedure was performed","None",NA,NA,NA,NA,NA,NA,NA,NA,NA,"Non-Expansion States",0,"No radiation to draining lymph nodes",0,0,NA,0,0,NA,"No radiation to draining lymph nodes",0,0,NA,0,"No radiation treatment",NA,"No radiation to draining lymph nodes",0,0,NA,0,"No radiation treatment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"","","",NA,"","",NA,"","",NA,"","",NA,"","",NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Facility 443",NA,NA,NA,NA,NA,NA,"T1","N0","M0","cStage I","T1","N0",NA,"pStage I","Negative margin","Surgery","Surgery Negative margin","Surgery - Margins"
"D54462578-3374-4e88-a1b2-0814cece8633","VZDFCPSBKC","Comprehensive Community Cancer Program","South Atlantic",86,"Male","White","Non-Spanish; non-Hispanic","Private Insurance/Managed Care","$35,000-$45,999","14% - 19.9%","Counties in metro areas of 1 million population or more","$48,000-$62,999","7%-12.9%","Metro areas >= 1 million",35.4,"Total Charlson score of 1",0,"Initial diagnosis elsewhere and part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere.",2010,"C446","Origin of primary is left.",8721,"Invasive or microinvasive","Cell type not determined, not stated or not applicable;unknown primaries; high grade dysplasia (adenocarcinoma in situ)","Positive histology",NA,0,2,NA,"No surgical diagnosis or staging performed","cT2b","cN0","cM0","cStage IIA","pT2b","pN0",NA,"pStage IIA","7th Edition","Stage II",0,1,200,3,"None","None","None","None","None",132,10,5,999,999,999,4,0,999,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,20550,40,40,40,45,"Open or approach unspecified.","No residual tumor","Regional lymph node surgery","None",0,"None","Surgery performed",NA,"No radiation treatment",0,0,"Radiation therapy was not administered because it was not part of the planned first course treatment",NA,NA,"None, chemotherapy was not part of the planned first course of therapy",NA,"None, hormone therapy was not part of the planned first course of therapy",NA,"None, immunotherapy was not part of the planned first course of therapy","No transplant procedure or endocrine therapy was administered as part of first course therapy","No systemic therapy and/or surgical procedures",NA,"None","None","Treatment given","Alive","Alive",118.77,"Alive",45,"None, chemotherapy was not part of the planned first course of therapy","None, immunotherapy was not part of the planned first course of therapy","None, hormone therapy was not part of the planned first course of therapy","None","Only one CoC facility reported this case to NCDB",1,NA,"No surgical diagnostic or staging procedure was performed","None",NA,NA,NA,"None",NA,"None",NA,"6.3% - 10.8%","63,333+","Non-Expansion States",0,"No radiation to draining lymph nodes",0,0,NA,0,0,NA,NA,NA,NA,NA,0,"No radiation treatment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"","","",NA,"","",NA,"","",NA,"","",NA,"","",NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Less than 5.0%","$74,063+",NA,NA,NA,"Facility 1127","Metro",NA,NA,NA,NA,NA,"T2","N0","M0","cStage II","T2","N0",NA,"pStage II","Negative margin","Surgery","Surgery Negative margin","Surgery - Margins"
"D87560b7a-3486-41ae-908f-1c09e438664b","JXMKMQJUTT","Academic/Research Program (includes NCI-designated comprehensive cancer centers)","South Atlantic",47,"Female","White","Non-Spanish; non-Hispanic","Private Insurance/Managed Care","$46,000 or more","Less than 14%","Counties in metro areas of 250,000 to 1 million population","$63,000 or more","7%-12.9%","Metro areas of 250,000 to 1 million",6.8,"Total Charlson Score of 0",0,"Initial diagnosis at the reporting facility and all of first course treatment or a decision not to treat was done at the reporting facility.",2019,"C446","Origin of primary is left.",8721,"Invasive or microinvasive",NA,"Positive histology",NA,0,1,0,"Biopsy done to the primary site",NA,NA,NA,NA,NA,NA,NA,NA,NA,"Stage II",NA,NA,NA,NA,NA,NA,NA,NA,"None",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,30,30,31,"Open or approach unspecified.","No residual tumor","Regional lymph node surgery","None",0,"None","Surgery performed",NA,"No radiation treatment",0,0,"Radiation therapy was not administered because it was not part of the planned first course treatment",NA,NA,"None, chemotherapy was not part of the planned first course of therapy",NA,"None, hormone therapy was not part of the planned first course of therapy",NA,"None, immunotherapy was not part of the planned first course of therapy","No transplant procedure or endocrine therapy was administered as part of first course therapy","No systemic therapy and/or surgical procedures",NA,"None","None","Treatment given","Alive","Alive",8.31,"Alive",31,"None, chemotherapy was not part of the planned first course of therapy","None, immunotherapy was not part of the planned first course of therapy","None, hormone therapy was not part of the planned first course of therapy","None","Only one CoC facility reported this case to NCDB",1,2,"A biopsy (incisional, needle, or aspiration) was done to the primary site","None",NA,"None","None",NA,"None",NA,"None","Less than 6.3%","63,333+","Non-Expansion States",0,"No radiation to draining lymph nodes",0,0,NA,0,0,NA,NA,NA,NA,NA,0,"No radiation treatment",NA,NA,NA,NA,NA,NA,NA,0,"No radiation treatment",0,NA,NA,NA,NA,NA,NA,NA,NA,"47","cM0","cN0",NA,"2A","cT2",NA,"cM0","pN0",NA,"2A","pT2",NA,"","",NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2.0",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"9","9",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,"XXXXX.9","XX9",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"01",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,470,NA,1,0,NA,NA,NA,NA,0,30,NA,NA,"Less than 5.0%","$74,063+",NA,NA,NA,"Facility 529","Metro",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Negative margin","Surgery","Surgery Negative margin","Surgery - Margins"
"Dc3c34b0d-d7cd-4591-aa96-9b32261d88f1","GWKZWRCTRA","Comprehensive Community Cancer Program","Pacific",81,"Female","White","Non-Spanish; non-Hispanic","Private Insurance/Managed Care",NA,NA,"Counties in metro areas of 1 million population or more","$63,000 or more","7%-12.9%","Metro areas >= 1 million",3.2,"Total Charlson Score of 0",1,"Initial diagnosis at the reporting facility, and part or all of first course treatment or a decision not to treat was at the reporting facility, NOS.",2010,"C446","Origin of primary is left.",8720,"In situ","Cell type not determined, not stated or not applicable;unknown primaries; high grade dysplasia (adenocarcinoma in situ)","Positive histology",NA,NA,0,0,"Biopsy done to the primary site","pTis","cN0","cM0","cStage 0","pTis","pNX",NA,"pStage 0","7th Edition","Stage 0",0,0,0,3,"None","None","None","None","Unknown",0,0,5,998,998,998,999,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,20550,33,33,33,35,"Open or approach unspecified.","No residual tumor","No regional lymph node surgery","None",0,"None","Surgery performed",NA,"No radiation treatment",0,0,"Radiation therapy was not administered because it was not part of the planned first course treatment",NA,NA,"None, chemotherapy was not part of the planned first course of therapy",NA,"None, hormone therapy was not part of the planned first course of therapy",NA,"None, immunotherapy was not part of the planned first course of therapy","No transplant procedure or endocrine therapy was administered as part of first course therapy","No systemic therapy and/or surgical procedures",NA,"None","None","Treatment given","Alive","Alive",137,"Alive",35,"None, chemotherapy was not part of the planned first course of therapy","None, immunotherapy was not part of the planned first course of therapy","None, hormone therapy was not part of the planned first course of therapy","None","Only one CoC facility reported this case to NCDB",1,NA,"A biopsy (incisional, needle, or aspiration) was done to the primary site","None",NA,NA,NA,"None",NA,"None",NA,"Less than 6.3%","63,333+","January 2014 Expansion States",0,"No radiation to draining lymph nodes",0,0,NA,0,0,NA,"No radiation to draining lymph nodes",0,0,NA,0,"No radiation treatment",NA,NA,NA,NA,NA,NA,NA,0,"No radiation treatment",0,NA,NA,NA,NA,NA,NA,NA,NA,"","","",NA,"","",NA,"","",NA,"","",NA,"","",NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"5.0% - 9.0%","$74,063+",NA,NA,NA,"Facility 364","Metro",NA,NA,NA,NA,NA,"cIs or similar","N0","M0","cStage 0","cIs or similar","NX",NA,"pStage 0","Negative margin","Surgery","Surgery Negative margin","Surgery - Margins"
"D64bcf370-7832-45ec-8997-bb2d9394f62d","JXMKMQJUTT","Academic/Research Program (includes NCI-designated comprehensive cancer centers)","South Atlantic",68,"Male","White","Non-Spanish; non-Hispanic","Medicare",NA,NA,"Urban population of 20,000 or more, adjacent to a metro area.","$63,000 or more","Less than 7%","Urban areas of 20,000 or more, adjacent to a metro area",63.3,"Total Charlson Score of 0",2,"Initial diagnosis at the reporting facility and all of first course treatment or a decision not to treat was done at the reporting facility.",2019,"C446","Origin of primary is right.",8720,"In situ",NA,"Positive histology",NA,NA,0,0,"Biopsy done to the primary site",NA,NA,NA,NA,NA,NA,NA,NA,NA,"Stage 0",NA,NA,NA,NA,NA,NA,NA,NA,"None",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,31,31,31,"Open or approach unspecified.","No residual tumor","No regional lymph node surgery","None",0,"None","Surgery performed",NA,"No radiation treatment",0,0,"Radiation therapy was not administered because it was not part of the planned first course treatment",NA,NA,"None, chemotherapy was not part of the planned first course of therapy",NA,"None, hormone therapy was not part of the planned first course of therapy",NA,"None, immunotherapy was not part of the planned first course of therapy","No transplant procedure or endocrine therapy was administered as part of first course therapy","No systemic therapy and/or surgical procedures",NA,"None","None","Treatment given","Alive","Alive",17.41,"Alive",31,"None, chemotherapy was not part of the planned first course of therapy","None, immunotherapy was not part of the planned first course of therapy","None, hormone therapy was not part of the planned first course of therapy","None","Only one CoC facility reported this case to NCDB",1,0,"A biopsy (incisional, needle, or aspiration) was done to the primary site","None",14,"None","None",NA,"None",NA,"None",NA,NA,"Non-Expansion States",0,"No radiation to draining lymph nodes",0,0,NA,0,0,NA,NA,NA,NA,NA,0,"No radiation treatment",NA,NA,NA,NA,NA,NA,NA,0,"No radiation treatment",0,NA,NA,NA,NA,NA,NA,NA,NA,"47","cM0","cN0",NA,"0","cTis",NA,"","",NA,"99","",NA,"","",NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"XX.9",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"9","9",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,"XXXXX.9","XX9",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"X9",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,470,NA,0,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,"Facility 529",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Negative margin","Surgery","Surgery Negative margin","Surgery - Margins"
"Db7357878-89ac-4f9c-912d-ca92837e5a04","JXMKMQJUTT","Academic/Research Program (includes NCI-designated comprehensive cancer centers)","South Atlantic",56,"Male","White","Non-Spanish; non-Hispanic","Private Insurance/Managed Care","$46,000 or more","Less than 14%",NA,"$63,000 or more","Less than 7%",NA,285.2,"Total Charlson score of 2",0,"Initial diagnosis elsewhere and all or part of first course treatment or a decision not to treat was done at the reporting facility, NOS.",2008,"C445","Paired site, but lateral origin unknown; midline tumor.",8743,"Invasive or microinvasive","Cell type not determined, not stated or not applicable;unknown primaries; high grade dysplasia (adenocarcinoma in situ)","Positive histology",NA,0,3,NA,"No surgical diagnosis or staging performed","cT2a","cN0","cM0","cStage IB","pT2","pN0",NA,"pStage IB","6th Edition","Stage I",0,0,300,3,NA,NA,NA,NA,NA,125,0,0,998,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,988,20550,0,0,20,45,NA,"No residual tumor","Regional lymph node surgery","None",NA,"None","Surgery performed",NA,"No radiation treatment",0,0,"Radiation therapy was not administered because it was not part of the planned first course treatment",NA,NA,"None, chemotherapy was not part of the planned first course of therapy",NA,"None, hormone therapy was not part of the planned first course of therapy",NA,"None, immunotherapy was not part of the planned first course of therapy","No transplant procedure or endocrine therapy was administered as part of first course therapy","No systemic therapy and/or surgical procedures",NA,"None","None",NA,"Alive","Alive",144.43,"Alive",45,"None, chemotherapy was not part of the planned first course of therapy","None, immunotherapy was not part of the planned first course of therapy","None, hormone therapy was not part of the planned first course of therapy","None","Only one CoC facility reported this case to NCDB",1,NA,"No surgical diagnostic or staging procedure was performed","None",NA,NA,NA,NA,NA,NA,NA,"Less than 6.3%","63,333+","Non-Expansion States",0,"No radiation to draining lymph nodes",0,0,NA,0,0,NA,NA,NA,NA,NA,0,"No radiation treatment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"","","",NA,"","",NA,"","",NA,"","",NA,"","",NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"","",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Less than 5.0%","$74,063+",NA,NA,NA,"Facility 529",NA,NA,NA,NA,NA,NA,"T2","N0","M0","cStage I","T2","N0",NA,"pStage I","Negative margin","Surgery","Surgery Negative margin","Surgery - Margins"
